Results 51 to 60 of about 15,373 (177)
Scientific ReportsFulvestrant, as the first selective estrogen receptor degrader, is widely used in the endocrine treatment of breast cancer. However, in the real world, there is a lack of relevant reports on adverse reaction data mining for fulvestrant.
Guisen Yin +3 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims The aim of this study is to evaluate the effects of multiple doses of esomeprazole, a strong proton pump inhibitor and acid‐reducing agent, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader.
Lana Tran +7 more
wiley +1 more source
Therapeutic Advances in Medical Oncology, 2017 We reviewed randomized phase II/III trials comparing first- or second-line endocrine therapy as monotherapy or in combination with targeted therapies for treatment of postmenopausal patients with hormone receptor-positive advanced breast cancer.
Tomás Reinert, Carlos H. Barrios
doaj +1 more source
Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patients. [PDF]
PLoS ONE, 2014 Fulvestrant is a selective estrogen receptor antagonist. Based on the measured growth inhibition of 60 human cancer cell lines (NCI60) in the presence of fulvestrant, as well as the baseline gene expression of the 60 cell lines, a gene expression score ...
Steen Knudsen +7 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Abemaciclib increases serum creatinine by inhibiting renal tubular transporters rather than reducing true glomerular filtration rate, a phenomenon known as pseudo‐acute kidney injury. Creatinine–cystatin C discrepancy and genetic determinants of this elevation remain insufficiently characterized in Japanese patients.
Hiroaki Watanabe +5 more
wiley +1 more source
Journal of Pharmacoeconomics and Pharmaceutical Management, 2015 Background: In this study we aim to assess the clinical evidence on the effectiveness of Fulvestrant compared with other alternatives to explore whether it has any advantage in the treatment outcomes of postmenopausal advanced breast cancer or not ...
Amir Hashemi-Meshkini +4 more
doaj
Frontiers in Oncology, 2022 The prognosis for female patients with locoregionally recurrent breast cancer has improved with the concurrent local and systemic treatment under multiple disciplinary teams.
Jingxian Ding, Yali Cao, Yonghong Guo
doaj +1 more source
Smart Molecules, EarlyView.AI is transforming TPD by improving the design, prediction, and optimization of degraders such as PROTACs, molecular glues, and LYTACs. This review summarizes key AI‐driven advances, highlights applications across drug discovery stages, and discusses remaining challenges and future directions for accelerating the development of therapies against ...
Shuanglin Qin +10 more
wiley +1 more source
Fulvestrant inhibits DU145 cell growth, migration, and invasion.
, 2014 (A) Fulvestrant induces growth inhibition of DU145 cells via an ERβ-dependent mechanism. Growth of the fulvestrant-treated DU145 cells with or without ERβ siRNA knockdown for 4 days relative to the ethanol-treated control cells with negative-control ...
Queeny Kwan-Yi Chan (565317) +8 more
core +1 more source
Pharmacophore modeling for identification of anti-IGF-1R drugs and in-vitro validation of fulvestrant as a potential inhibitor. [PDF]
PLoS ONE, 2018 Insulin-like growth factor 1 receptor (IGF-1R) is an important therapeutic target for breast cancer treatment. The alteration in the IGF-1R associated signaling network due to various genetic and environmental factors leads the system towards metastasis.
Samra Khalid +4 more
doaj +1 more source